Back to top
more

CONMED (CNMD)

(Delayed Data from NYSE)

$54.67 USD

54.67
552,572

+1.29 (2.42%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $54.66 -0.01 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (76 out of 244)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's Why You Should Invest in Surmodics (SRDX) Stock Now

by Zacks Equity Research

Surmodics (SRDX) is gaining from consistent growth In Vitro Diagnostics (IVD) unit and persistent efforts to boost R&D functionalities.

Zacks Equity Research

Ecolab (ECL) Expands Product Portfolio With New Technology

by Zacks Equity Research

Ecolab (ECL) made an enhancement in its healthcare offerings with new technology that will improve standard of care for hospitals.

Zacks Equity Research

Here's Why You Should Hold on to Cardinal Health (CAH) Stock

by Zacks Equity Research

Cardinal Health (CAH) is gaining from diversified product portfolio and robust pharmaceutical segment. However, integration risks remain a concern.

Zacks Equity Research

What's in Store for Cooper Companies (COO) in Q3 Earnings?

by Zacks Equity Research

Better-than-expected performance at CVI and CSI and higher revenues are likely to aid Cooper Companies (COO) in Q3 earnings.

Zacks Equity Research

CONMED (CNMD) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Higher revenues, solid segmental performance and strong adjusted gross margins benefit CONMED's (CNMD) Q2 earnings. However, high long-term debt remains a concern.

Zacks Equity Research

Conmed (CNMD) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Conmed (CNMD) delivered earnings and revenue surprises of 5.66% and 2.22%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Conmed (CNMD) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Conmed (CNMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

LH vs. CNMD: Which Stock Is the Better Value Option?

by Zacks Equity Research

LH vs. CNMD: Which Stock Is the Better Value Option?

Zacks Equity Research

Here's Why You Should Invest in CONMED (CNMD) Stock Now

by Zacks Equity Research

CONMED (CNMD) continues to benefit from robust international sales, broad product portfolio and persistent focus on R&D.

Zacks Equity Research

Myriad Genetics' Elevate 2020 Plan Holds Promise Amid Issues

by Zacks Equity Research

Myriad Genetics (MYGN) unveils an 'Elevate 2020' program that aims to generate $50 million in incremental operating income by fiscal 2020.

Zacks Equity Research

Medtronic's Titan Spine Buyout to Boost Spine Surgery Range

by Zacks Equity Research

Medtronic's (MDT) comprehensive biologics portfolio clubbed with Titan Spine's surface-enhanced titanium implants can enhance patient outcomes in spinal procedures.

Zacks Equity Research

Walgreens Gains on Strategic Deals, Margin Pressure Remains

by Zacks Equity Research

Walgreens Boots' (WBA) Retail Pharmacy USA division is witnessing comparable prescription growth and also benefiting from a strong retail prescription market.

Zacks Equity Research

Thermo Fisher's Unit Sale May Not Ail Specialty Diagnostics

by Zacks Equity Research

The Anatomical Pathology business of Thermo Fisher (TMO) belongs to its Specialty Diagnostics segment that serves customers across healthcare and clinical laboratories.

Zacks Equity Research

Here's Why You Should Hold Varian Medical (VAR) Stock Now

by Zacks Equity Research

Varian (VAR) expects the Cancer Treatment Services International buyout to prove accretive to earnings per share during fiscal 2021.

Zacks Equity Research

Amedisys Rides on New Buyouts, Strength in Personal Care Arm

by Zacks Equity Research

Amedisys' (AMED) recently-integrated Personal Care segment is attaining stability and living up to expectation.

Zacks Equity Research

Veeva's Vault eTMF Implemented by South Korea's Celltrion

by Zacks Equity Research

Management at Veeva (VEEV) expects Vault subscription revenues to grow a significant 40% in fiscal 2020.

Zacks Equity Research

Patterson Companies' (PDCO) Earnings Miss Estimates in Q4

by Zacks Equity Research

Patterson Companies' (PDCO) Q4 results benefit from higher revenues, gross margin expansion and solid show by Animal Health segment.

Zacks Equity Research

Varian (VAR) & Tennessee Oncology to Implement Use of Noona

by Zacks Equity Research

Varian's (VAR) core Oncology unit gets a boost from the latest collaboration with Tennessee Oncology.

Zacks Equity Research

Here's Why You Should Invest in DENTSPLY SIRONA (XRAY) Now

by Zacks Equity Research

DENTSPLY (XRAY) focuses on innovation through active R&D.

Zacks Equity Research

Veeva's Submissions & RIM Implemented by Sumitomo Dainippon

by Zacks Equity Research

Veeva's (VEEV) flagship Vault platform witnesses robust demand.

Zacks Equity Research

Here's Why You Should Buy Masimo (MASI) Stock Right Now

by Zacks Equity Research

Masimo (MASI) receives FDA clearance for its O3 Regional Oximetry for utilization on neonatal and infant patients.

Zacks Equity Research

DaVita Divests DMG to Optum, Boosts Kidney Care Services

by Zacks Equity Research

The divestment of DMG boosts DaVita's (DVA) core Kidney Care business.

Zacks Equity Research

Here's Why You Should Hold PerkinElmer (PKI) Stock for Now

by Zacks Equity Research

PerkinElmer (PKI) raises earnings per share guidance for 2019.

Zacks Equity Research

Here's Why You Should Hold Baxter International (BAX) for Now

by Zacks Equity Research

Baxter (BAX) expects its bottom line to rise in the second quarter of 2019, courtesy to Renal Care and Clinical Nutrition businesses.

Zacks Equity Research

Here's Why Conmed (CNMD) is a Great Momentum Stock to Buy

by Zacks Equity Research

Does Conmed (CNMD) have what it takes to be a top stock pick for momentum investors? Let's find out.